All diseases

Disease Atlas / Disease detail

Kawasaki disease

An atlas of acute childhood vasculitis, clinical diagnosis, IVIG, and coronary-risk follow-up.

Kawasaki disease · mucocutaneous lymph node syndrome

MONDO:0012727Public QA completeSource-bound · 4

Disease at a glance

Start with the essentials, then explore the patient and research views.

Public revision · c1d6d8bbd16e

Disease class
Kawasaki disease is an acute vasculitis mainly affecting children.
Core mechanism
Its cause is not fully understood.
Genes or cause
Persistent fever and mucocutaneous findings are characteristic.
Typical features
Conjunctivitis, rash, lip, and extremity changes can occur.
Variability
Incomplete disease also carries coronary risk.
Diagnosis
Diagnosis is clinical without a single confirmatory test.
Management
Echocardiography evaluates the coronary arteries.
Treatment and research
Other febrile illnesses require exclusion.
Reading evidence
IVIG and aspirin are central initial treatments.
Key caution
Additional anti-inflammatory therapy is considered for high-risk patients.

For patients and families

A structured guide for understanding the disease and preparing for clinical conversations.

At a glance

Kawasaki disease is an acute vasculitis mainly affecting children.

Conjunctivitis, rash, lip, and extremity changes can occur.

How the disease works

Its cause is not fully understood.

Persistent fever and mucocutaneous findings are characteristic.

Why experiences vary

Incomplete disease also carries coronary risk.

Diagnosis and management

Diagnosis is clinical without a single confirmatory test.

Treatment status

Echocardiography evaluates the coronary arteries.

Other febrile illnesses require exclusion.

Reading clinical trials

Coronary status determines long-term follow-up.

Topics for a clinical visit

Onset date, echocardiography, and treatment response require review.

Medical notice

This material is for disease education and is not a personal diagnosis or treatment instruction.

Evidence and sources

A trial registry status does not establish efficacy or regulatory approval.